What is NSI-189

NSI‐189 is a small molecule with enhanced neurogenic activity and is already in clinical trial for the relief of major depressive disorder (MDD) and inhibition against suicide. Studies show that NSI‐189 promotes behavioral recovery in stroke, enhances cell proliferation and neurogenesis in stroke, upregulates neurogenic factors in tandem with neurogenesis.[1] NSI‐189 has been under investigation by Neuralstem Inc. for the relief from major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration.[2]  Additionally, the company Neuralstem Inc. has said that it intends to pursue clinical development of NSI-189 for a variety of other neurological conditions, including traumatic brain injury, Alzheimer’s disease, post-traumatic stress disorder, stroke, and to prevent cognitive and memory decline in aging.

Health Benefits of NSi-189

NSI-189 has nootropic effects and is most popularly used as an antidepressant. It is currently under the investigation of Neuralstem  Inc. The company has been testing it for use in major depression as well as for hindering cognitive impairments, and brain degeneration. NSI-189 is a multi-domain neurogenic compound with brain-therapeutic properties with potential therapeutic applications across disparate psychiatric disorders. The common health benefits of NSI-189 include:Reduces depression [3] Mitigates depressive symptoms and improve cognitive function [4] Benefits stroke patients [5] Helps increase neuron formation [6] Enhances neurogenic activity [3] Users report that it improves mood and traumatic brain injury People also report that it may help with diabetesAccording to Neuralstem Inc., NSI-189 is presently in preclinical trials for the following:Major Depressive Disorder Angelman Syndrome Cognitive Impairment Irradiation-induced cognition Diabetes-related neuropathy Ischemic Stroke

How NSI-189 works?

NSI-189 is a benzylpiperizine-aminiopyridine, a novel chemical entity that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and stimulates neurogenesis in murine hippocampus in vivo. Emerging evidence also shows that NSI-189 phosphate has regionally specific effects insofar as neurogenesis is observed largely in the subventricular zone of the hippocampus. Results from a preliminary proof of concept study suggests that NSI-189 may be capable of mitigating depressive symptoms and improve cognitive function in adults with DSM-5-defined Major Depressive Disorder (MDD). Primary proof-of-concept studies show both antidepressant and procognitive effects. Beneficial effects in cognitive-emotional processing as well as whether the procognitive effects are independent of antidepressant effects are vistas of future research. Taken together, NSI-189 is a multi-domain neurogenic compound with brain-therapeutic properties with potential therapeutic applications across disparate psychiatric disorders.

Consideration and Recomendation

Nootropics are usually free of adverse effects. Unlike other nootropics, NSI-189 is not entirely free from adverse effects. It comes with some side effects like:

Increased appetite
Increased dietary preference for sugar (sweet tooth)
Exercise intolerance
Post-exercise headaches
Decreased motivation

Consult your healthcare provider before using any supplement. Appropriate NSI-189 dose depends on several factors like the user’s age, health, and several other conditions. However, the usual doses have been between 40-80mgs daily. Initially, 40mgs are usually taken and then increases it to 80mgs. Consult your physician for your appropriate dosage.